+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06447103

Phase II Study of 89Zr-DFO-GmAb PETCT Versus Contrast-Enhanced CT to Detect Recurrent Clear Cell Renal Cell Cancer After Surgery

Led by Jonsson Comprehensive Cancer Center · Updated on 2026-06-15

91

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new imaging technique called 89Zr-DFO-GmAb PETCT compared to the standard contrast-enhanced CT scan for detecting the return of clear cell renal cell cancer after surgery. This phase II study focuses on patients with a high risk of cancer recurrence, aiming to determine if the new PETCT scan can better detect small or microscopic tumor cells that standard CT might miss. The study also examines the safety of the 89Zr-DFO-GmAb imaging agent and explores its ability to predict disease outcomes. Participants receive an intravenous injection of 89Zr-DFO-GmAb, a radioactive tracer that attaches to a protein found on clear cell renal cancer cells. One week later, they undergo a whole-body PETCT scan along with a standard contrast-enhanced CT scan. Additional imaging such as bone scans or brain MRI may be performed if medically needed. Blood samples are also collected during the study to support research objectives. After imaging, participants are followed for up to 24 months with scheduled visits at 8, 16, and 24 months to monitor their health and cancer status. Researchers assess how well the new PETCT detects cancer lesions compared to standard CT, monitor any side effects from the imaging agent, evaluate recurrence-free survival, and study various biological markers related to the cancer. This follow-up helps understand the potential clinical usefulness and safety of this investigational scan.

CONDITIONS

Brief Title

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here